Anti-CD3 antibody mutant, nucleotide sequence, recombinant expression vector and application thereof
By combating specific amino acid sequence mutations in the wild-type heavy chain variable region of CD3 antibody, the CD3 antigen affinity and stability of the antibody is improved, and the problem of insufficient affinity and stability of existing antibodies is solved, achieving more efficient tumor cell killing and immune cell activation.
Patent Information
- Application Number
- CN202310601512.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-12-03
AI Technical Summary
The existing anti-CD3 antibodies have insufficient affinity and stability, and it is difficult to effectively balance the affinity between the CD3 end and the antigen end of the target cell, affecting the therapeutic effect and the degree of activation of immune cells.
Targets are obtained by modifying the amino acid sequences of wild-type heavy chain variable regions of anti-CD3 antibodies, especially mutation sites such as position 30, position 102, position 105, position 106, position 108 and position 113. Anti-CD3 antibody mutants with high point affinity and significantly reduced aggregates improve antibody yield and stability.
It significantly improves the affinity of anti-CD3 antibodies with CD3 antigen, reduces the dosage, reduces the production of aggregates in the antibody, improves the yield and stability of the antibody, and enhances the killing ability of tumor cells.
Smart Images

Figure CN119060180A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetic engineering and immunotechnology, and in particular to anti-CD3 antibody mutants, nucleotide sequences, recombinant expression vectors and applications thereof. Background Art
[0002] T lymphocytes are lymphocyte stem cells derived from the bone marrow. After differentiation and maturation in the thymus, they are transported to immune organs and tissues throughout the body through lymphatic and blood circulation to exert immune functions. T cells are highly efficient killer cells. Under physiological conditions, through the formation of immune synapses, they can quickly release cytotoxins and cytokines, which can quickly kill and eliminate cells and tumor cells infected by exogenous sources. The formation of immune synapses is highly dependent on the complex formed by TCR (T cell receptor) recognizing the Major Histocompatibility Complex (MHC) on the surface of antigen-presenting cells and the presented antigen peptides.
[0003] CD3 is a transmembrane protein located on the surface of mature T cells, including four subtypes: CD3δ, CD3ε, CD3γ, and CD3ζ. Under physiological conditions, CD3 antigens on T cells mostly exist in the form of two heterodimers, CD3δ / CD3ε and CD3γ / CD3ε, which can non-covalently bind to the α chain and β chain of TCR to form a complete TCR-CD3 complex, which has the function of stabilizing the TCR structure and transmitting activation signals, and can activate the necessary downstream pathways for immune cell activation and initiate intracellular cascade reactions. Antibody drugs targeting CD3 usually recognize the CD3ε chain in natural heterodimers, thereby activating or blocking the signal transduction of T cell activation, eliminating effector T cells or inducing the production of regulatory T cells, providing a new method for treating organ transplant rejection and autoimmune diseases. The use of CD3 monoclonal antibody drugs to activate T cells can be traced back to the mid-1980s, when the anti-CD3 antibody OKT3 isolated from hybridomas showed anti-tumor cytotoxicity. As the first therapeutic antibody to be marketed, OKT3 has a milestone influence. In addition, SP34 is one of the few open-source CD3 antibodies that can simultaneously recognize CD3ε chains of different species with no significant difference in affinity.
[0004] With the development of tumor immunotherapy drugs, bispecific antibodies and even multispecific antibodies formed by the combination of CD3 and tumor-associated antigen targets have emerged in people's field of vision. Bispecific or multispecific antibodies can bridge TCR receptors of T cells by targeting CD3 antigens on the surface of T cells at one end, and bridge target cells by targeting antigens on the surface of tumor cells at the other end, thereby breaking through the distance limit between cytotoxic T cells (CTL) and tumor cells, promoting the formation of immune synapses, and directly activating T cells, inducing T cells to directly kill tumor cells, without relying on the traditional dual activation signals of T cells.
[0005] Existing studies have shown that the affinity of the anti-CD3 antibody end binding to CD3 on the surface of immune cells can not only affect the duration of action of the antibody drug, but also affect the activation of immune cells by anti-CD3 antibodies or multispecific antibodies containing anti-CD3 ends. In addition, the affinity of CD3 may affect the pharmacokinetic parameters, tissue distribution, and cellular uptake of antibody drugs. Genetech's research on CD3 / Her2 bispecific antibodies found that low CD3 affinity makes antibodies more likely to be distributed in Her2-positive tumor sites, while high CD3 affinity makes antibodies more likely to be distributed in T-cell-rich tissues (such as the spleen and lymph nodes). Therefore, how to balance the affinity of the CD3 end and the target cell antigen end in bispecific or multispecific antibodies, improve the therapeutic window, and coordinate the degree of activation of human immune cells while the antibodies exert their anti-tumor activity is a difficult point in the current research and development work to achieve the best results.
[0006] In existing studies on bispecific antibodies and polyspecific antibodies, the anti-CD3 antibody end preferably uses monovalent binding or reduces the exposure of the antibody end, which significantly affects the ability of the anti-CD3 antibody end to bind to immune cells. Modification of the amino acid sequence of the antibody-antigen binding epitope can be used to adjust the affinity of the antibody to the target. How to improve the affinity of the antibody while increasing the yield and stability is still one of the current research focuses. Summary of the invention
[0007] In view of this, the present invention modifies the amino acid sequence of the heavy chain variable region of the existing wild-type anti-CD3 antibody to obtain a series of complete anti-CD3 antibody mutants with high target affinity and significantly reduced aggregates, and the yield and stability of the antibody are also significantly improved.
[0008] In a first aspect, the present invention provides an anti-CD3 antibody mutant, the anti-CD3 antibody mutant comprising a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is obtained by mutating at least one amino acid in the amino acid sequence of the heavy chain variable region of the wild-type anti-CD3 antibody shown in SEQ ID NO: 1;
[0009] The mutation sites of the amino acid sequence shown in SEQ ID NO: 1 include at least one mutation site among positions 30, 102, 105, 106, 108 and 113.
[0010] In some embodiments, the N at position 30 of the amino acid sequence shown in SEQ ID NO:1 is substituted with Q.
[0011] In some embodiments, the G at position 102 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of H, Q, and S. Preferably, the G at position 102 is substituted with S.
[0012] In some embodiments, the G at position 105 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, H, M, N, P, and Q. Preferably, the G at position 105 is substituted with any one of A, H, N, P, and Q.
[0013] In some embodiments, the N at position 106 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, D, K, Q, and Y. Preferably, the N at position 106 is substituted with D.
[0014] In some embodiments, the Y at position 108 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, D, F, G, H, I, K, L, R, S, and W. Preferably, the Y at position 108 is substituted with any one of G, H, K, R, and S.
[0015] In some embodiments, the A at position 113 of the amino acid sequence shown in SEQ ID NO:1 is substituted with E.
[0016] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is selected from any one of the amino acid sequence shown in SEQ ID NO:9, the amino acid sequence shown in SEQ ID NO:11, the amino acid sequence shown in SEQ ID NO:13, the amino acid sequence shown in SEQ ID NO:15, the amino acid sequence shown in SEQ ID NO:17, the amino acid sequence shown in SEQ ID NO:19, the amino acid sequence shown in SEQ ID NO:21, the amino acid sequence shown in SEQ ID NO:23, the amino acid sequence shown in SEQ ID NO:25, the amino acid sequence shown in SEQ ID NO:27, the amino acid sequence shown in SEQ ID NO:29, the amino acid sequence shown in SEQ ID NO:31, the amino acid sequence shown in SEQ ID NO:33, the amino acid sequence shown in SEQ ID NO:35, the amino acid sequence shown in SEQ ID NO:37, the amino acid sequence shown in SEQ ID NO:39, the amino acid sequence shown in SEQ ID NO:41 and the amino acid sequence shown in SEQ ID NO:43.
[0017] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is as shown in SEQ ID NO:9, which is encoded by the nucleotide sequence shown in SEQ ID NO:10.
[0018] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is as shown in SEQ ID NO:11, which is encoded by the nucleotide sequence shown in SEQ ID NO:12.
[0019] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is as shown in SEQ ID NO:13, which is encoded by the nucleotide sequence shown in SEQ ID NO:14.
[0020] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is as shown in SEQ ID NO:15, which is encoded by the nucleotide sequence shown in SEQ ID NO:16.
[0021] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 17, which is encoded by the nucleotide sequence shown in SEQ ID NO: 18.
[0022] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is as shown in SEQ ID NO: 19, which is encoded by the nucleotide sequence shown in SEQ ID NO: 20.
[0023] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 21, which is encoded by the nucleotide sequence shown in SEQ ID NO: 22.
[0024] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 23, which is encoded by the nucleotide sequence shown in SEQ ID NO: 24.
[0025] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 25, which is encoded by the nucleotide sequence shown in SEQ ID NO: 26.
[0026] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 27, which is encoded by the nucleotide sequence shown in SEQ ID NO: 28.
[0027] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 29, which is encoded by the nucleotide sequence shown in SEQ ID NO: 30.
[0028] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:31, which is encoded by the nucleotide sequence shown in SEQ ID NO:32.
[0029] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 33, which is encoded by the nucleotide sequence shown in SEQ ID NO: 34.
[0030] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 35, which is encoded by the nucleotide sequence shown in SEQ ID NO: 36.
[0031] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:37, which is encoded by the nucleotide sequence shown in SEQ ID NO:38.
[0032] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 39, which is encoded by the nucleotide sequence shown in SEQ ID NO: 40.
[0033] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:41, which is encoded by the nucleotide sequence shown in SEQ ID NO:42.
[0034] In some embodiments, the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:43, which is encoded by the nucleotide sequence shown in SEQ ID NO:44.
[0035] In some embodiments, the amino acid sequence of the light chain variable region of the anti-CD3 antibody mutant is shown as SEQ ID NO:5, and the nucleotide sequence of the light chain variable region is shown as SEQ ID NO:6.
[0036] In a second aspect, the present invention provides a nucleotide sequence of a heavy chain variable region of an anti-CD3 antibody mutant, which encodes the anti-CD3 antibody mutant described in the first aspect.
[0037] In some embodiments, the nucleotide sequence of the heavy chain variable region of the anti-CD3 antibody mutant is selected from any one of the nucleotide sequence shown in SEQ ID NO: 10, the nucleotide sequence shown in SEQ ID NO: 12, the nucleotide sequence shown in SEQ ID NO: 14, the nucleotide sequence shown in SEQ ID NO: 16, the nucleotide sequence shown in SEQ ID NO: 18, the nucleotide sequence shown in SEQ ID NO: 20, the nucleotide sequence shown in SEQ ID NO: 22, the nucleotide sequence shown in SEQ ID NO: 24, the nucleotide sequence shown in SEQ ID NO: 26, the nucleotide sequence shown in SEQ ID NO: 28, the nucleotide sequence shown in SEQ ID NO: 30, the nucleotide sequence shown in SEQ ID NO: 32, the nucleotide sequence shown in SEQ ID NO: 34, the nucleotide sequence shown in SEQ ID NO: 36, the nucleotide sequence shown in SEQ ID NO: 38, the nucleotide sequence shown in SEQ ID NO: 40, the nucleotide sequence shown in SEQ ID NO: 42 and the nucleotide sequence shown in SEQ ID NO: 44.
[0038] In a third aspect, the present invention provides a recombinant expression vector comprising the nucleotide sequence described in the second aspect.
[0039] In some embodiments, the recombinant expression vector is a eukaryotic expression vector, and the eukaryotic expression vector comprises the nucleotide sequence described in the second aspect.
[0040] The present invention also provides use of the anti-CD3 antibody mutant described in the first aspect in a drug for inhibiting or treating cancer.
[0041] In the application of the present invention, the cancer is selected from the following cancers or occurs in the following parts: colon cancer, breast cancer, ovarian cancer, pancreatic cancer, stomach cancer, prostate cancer, kidney cancer, cervical cancer, bone marrow cancer, lymphoma cancer, leukemia cancer, thyroid cancer, endometrial cancer, uterine cancer, bladder cancer, neuroendocrine cancer, head and neck cancer, liver cancer, nasopharyngeal cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell skin cancer, squamous cell skin cancer, dermatofibrosarcoma protuberans, Merkel cell cancer, glioblastoma, glioma, sarcoma, mesothelioma and myelodysplastic syndrome.
[0042] Compared with the prior art, the present invention has at least the following beneficial effects:
[0043] (1) The anti-CD3 antibody mutant provided by the present invention has significantly improved affinity for CD3 antigen, which can reduce the dosage of antibody administration.
[0044] (2) The anti-CD3 antibody mutant provided by the present invention can reduce the generation of intra-antibody aggregates, and the yield and stability of the antibody are significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0046] Figure 1 This is a non-reducing SDS-PAGE electrophoresis diagram of the anti-CD3 antibody mutants 1 to 7 provided in the examples of the present application;
[0047] Figure 2 The reduced SDS-PAGE electrophoresis diagram of the anti-CD3 antibody mutants 1 to 7 provided in the examples of the present application;
[0048] Figure 3 This is a SEC-HPLC chromatogram of the wild-type anti-CD3 antibody provided in the examples of the present application;
[0049] Figure 4a SEC-HPLC chromatograms of anti-CD3 antibody mutants 1 to 9 provided in the examples of the present application;
[0050] Figure 4b SEC-HPLC chromatograms of anti-CD3 antibody mutants 10 to 18 provided in the examples of the present application;
[0051] Figure 5This is a graph showing the target binding activity of the anti-CD3 antibody mutants 1 to 7 provided in the examples of the present application to Jurkat cells that naturally express CD3. DETAILED DESCRIPTION
[0052] In order to better understand the technical solution of the present invention, the embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0053] It should be clear that the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0054] The terms used in the embodiments of the present invention are only for the purpose of describing specific embodiments, and are not intended to limit the present invention. The singular forms "a", "said" and "the" used in the embodiments of the present invention and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.
[0055] It should be understood that the term "and / or" used in this article is only a description of the association relationship of associated objects, indicating that there can be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article generally indicates that the associated objects before and after are in an "or" relationship.
[0056] Antibodies are generally understood by those skilled in the art, and refer to immunoglobulins (Ig) that can specifically bind to antigens.
[0057] Antibodies (Ig) are composed of four polypeptide chains, each of which is connected by a varying number of interchain disulfide bonds. Ig can form a "V-shaped structure" called an Ig monomer, which is the basic unit of antibodies.
[0058] Antibody molecules contain four heterologous polypeptide chains, of which the two chains with larger molecular weight are called heavy chains (HC) and the two chains with smaller molecular weight are called light chains (LC). The amino acid composition of the two heavy chains and the two light chains in the same antibody molecule is exactly the same.
[0059] The sequences of about 110 amino acids near the N-terminus of the heavy and light chains vary greatly, while the sequences of the other parts are relatively constant. Therefore, the regions of the light and heavy chains with large changes in amino acid sequences near the N-terminus are called variable regions (V), accounting for 1 / 4 and 1 / 2 of the heavy and light chains, respectively; the regions with relatively stable amino acid sequences near the C-terminus are called constant regions (C), accounting for 3 / 4 and 1 / 2 of the heavy and light chains, respectively.
[0060] Research has found that improving the affinity of anti-CD3 antibodies can enable them to achieve better T cell activation and killing effects. Mutating the amino acid sequence of the variable region of the antibody can be used to improve hydrophilicity, hydrophobicity and charge, while also reducing immunogenicity, stabilizing the antibody structure, reducing aggregation or degradation, etc. In addition, site-directed mutagenesis based on the variable region of the antibody can improve the yield and stability of the anti-CD3 single-chain antibody.
[0061] The technical solution of the present invention is further described below in conjunction with embodiments.
[0062] Example 1: Screening of anti-CD3 antibody mutants
[0063] First, the variable regions of the wild-type heavy and light chains of the anti-CD3 antibody (clone number SP-34) were mutated using site-directed mutagenesis technology to obtain a series of saturation mutations of anti-CD3 antibody mutants. Among them, the heavy chain variable region (CD3-HC) of the anti-CD3 antibody mutant was mutated using the amino acid sequence of the heavy chain variable region of the wild-type anti-CD3 antibody (as shown in SEQ ID NO: 1) as a template; the amino acid sequence of the heavy chain constant region of the anti-CD3 antibody mutant was the same as the amino acid sequence of the heavy chain constant region of the wild-type anti-CD3 antibody. In the present application, the amino acid sequence of the heavy chain constant region of the wild-type anti-CD3 antibody is shown in SEQ ID NO: 3.
[0064] SEQ ID NO: 1: Amino acid sequence of the heavy chain variable region of the wild-type anti-CD3 antibody (341PR).
[0065] SEQ ID NO: 2: Nucleotide sequence of the heavy chain variable region of the wild-type anti-CD3 antibody (341PL).
[0066] SEQ ID NO: 3: Amino acid sequence of the heavy chain constant region of the wild-type anti-CD3 antibody.
[0067] SEQ ID NO: 4: Nucleotide sequence of the heavy chain constant region of the wild-type anti-CD3 antibody.
[0068] In the present application, the amino acid sequence of the light chain variable region of the anti-CD3 antibody mutant is the same as the amino acid sequence of the light chain variable region of the anti-CD3 antibody wild-type (such as SEQ ID NO: 5), and the amino acid sequence of the light chain constant region of the anti-CD3 antibody mutant is the same as the amino acid sequence of the light chain constant region of the anti-CD3 antibody wild-type. In the present application, the amino acid sequence of the light chain constant region of the anti-CD3 antibody wild-type is shown in SEQ ID NO: 7.
[0069] SEQ ID NO: 5: Amino acid sequence of the light chain variable region of the wild-type anti-CD3 antibody (342PR).
[0070] SEQ ID NO: 6: Nucleotide sequence of the light chain variable region of the wild-type anti-CD3 antibody (342PL).
[0071] SEQ ID NO: 7: Amino acid sequence of the light chain constant region of the wild-type anti-CD3 antibody.
[0072] SEQ ID NO: 8: Nucleotide sequence of the light chain constant region of the wild-type anti-CD3 antibody.
[0073] Second, antibody expression: The wild-type and mutant anti-CD3 antibody plasmids were inoculated into SOB (Super Optimal Broth) liquid medium containing ampicillin, placed in a 37°C constant temperature shaker, and cultured overnight at 220 rpm. The high-purity plasmid was extracted using an endotoxin-free plasmid mini-extraction kit (purchased from Tiangen Biochemical Technology, item number DP118), and the plasmid concentration was determined using a Nanodrop micro-spectrophotometer.
[0074] Cell transfection reagents were purchased from Thermo Fisher Scientific Inc., USA. One day before transfection, ExpiCHO-S cells were cultured at 3×10 6 ~4×10 6 On the day of transfection, the cell density reached 7×10 6 ~10×10 6 cells / mL, and the cell viability should be >95%. Before transfection, dilute the cells to 6×10 6 cells / mL, mix gently and dispense 0.5 mL per well into a 96-well deep-well plate.
[0075] Prepare transfection complex: first add 400ng DNA to 20μL Gibco TM OptiPRO TM Gently pipette and mix to make a DNA dilution solution; then add 1.6 μL ExpiFectamine TM CHO reagent was added with 20 μL Gibco TM OptiPRO TM In SFM, gently pipette to mix to make a transfection reagent diluent; mix the two, gently pipette to mix, and let stand at room temperature for 1 to 5 minutes to form ExpiFectamine TM Add the transfection complex to the ExpiCHO-S cells and shake well. Place the cells at 37°C, 90% humidity, and 8% CO 2The cells were incubated in a cell culture shaker (shaking speed 900 rpm, orbital diameter 3 mm). 18 to 22 hours after transfection, ExpiFectamine was added according to the standard culture protocol TM CHOEnhancer and ExpiCHO TM Feed, then place the 96-well plate back into the 8% CO 2 Continue incubation in a 37°C cell culture shaker. Collect the supernatant 7 to 8 days after transfection.
[0076] Antibody quantification: The antibody concentration in the culture supernatant of ExpiCHO-S cells was determined by conventional ELISA method. The specific steps are as follows: One day before the experiment, a 96-well ELISA plate was coated with Goat anti-human IgG Fc antibody (final concentration 0.5 μg / mL) and placed at 4°C for overnight coating. On the day of the experiment, the coating solution was discarded, washed 3 times with 1×PBS-T buffer, and 1×PBS containing 5% BSA was added to it for blocking at room temperature for 2 hours. After the blocking was completed, the blocking solution was discarded, and the diluted ExpiCHO-S cell culture supernatant and standard curve sample (human IgG) were added to each well, respectively, and placed in a shaker for reaction at room temperature for 1 hour. After the reaction was completed, the liquid in the plate was discarded, washed 3 times with 1×PBS-T buffer, and diluted Goat anti-human IgG (HRP) (purchased from Promega) was added to each well in turn, and reacted at room temperature for 0.5 hours. After the reaction was completed, the liquid in the plate was discarded, and washed 5 times with 1×PBS-T buffer, soaking for about 1 minute each time. After washing, 100 μL of TMB colorimetric solution (purchased from Solebo) was added to each well and the reaction was carried out in the dark for 5 minutes. 100 μL of ELISA stop solution (purchased from Solebo) was added to each well, and the blue color immediately turned yellow. The absorbance value was recorded at 450 nm using a multifunctional microplate reader (purchased from BioTek), and a standard curve was drawn with antibody concentration-OD450, and the antibody concentration in the cell culture supernatant was calculated based on this.
[0077] Determination of the binding activity of antibodies to CD3 protein:
[0078] Jurkat cell line, a human lymphocytic leukemia cell line that highly expresses natural CD3, was cultured in RPMI-1640 medium (purchased from Thermo Fisher Scientific, USA) containing 10% FBS (purchased from Thermo Fisher Scientific, USA) and double antibody (purchased from Shanghai Biotime Biotechnology Co., Ltd.), and passaged every 2 to 3 days.
[0079] Take Jurkat cell lines in the logarithmic growth phase, count the cells, wash the cell mass with 1×PBS buffer, and centrifuge at 250×g for 5 minutes. Resuspend the cells in 1×PBS buffer and inoculate them in a 96-well V-bottom culture plate (purchased from NEST), add 50μL of cell suspension to each well, and the cell density is 5×105 cells / well. Add 50μL of gradient dilution of the test antibody to each well, so that the final protein concentration is 10nM, 2nM, 0.4nM, 0.08nM, 0.016nM, 0.0032nM, 0.00064nM and 0.000128nM, respectively. The cell wells without antibody are used as negative controls and incubated at 4°C for 0.5 hours. Wash the cells twice with PBS, centrifuge at 250×g for 5 minutes each time. 100 μL of the secondary antibody Goat anti-Human IgGFc Secondary Antibody PE (purchased from Thermo Fisher Scientific, catalog number 12-4998-82) diluted 1:200 in PBS was added and incubated at 4°C for 0.5 hours. The cells were washed twice with PBS, centrifuged at 250×g for 5 minutes each time, resuspended in PBS, and the mean fluorescence intensity value was read using a CytoFLEX flow cytometer (purchased from Beckman Coulter), and the results were analyzed and data processed using Graphpad Prism.
[0080] After testing, the EC50 concentrations of the wild-type anti-CD3 antibody and the anti-CD3 antibody mutant binding to the target of the Jurkat cell line at different concentrations are shown in Table 1.
[0081] Table 1. EC50 concentrations of wild-type anti-CD3 antibodies and anti-CD3 antibody mutants binding to targets at the cellular level
[0082]
[0083] Note: In the table, the meanings of numbers such as CD3-HC-N030Q and CD3-HC-G102H are: taking CD3-HC-N030Q as an example, it means that the 30th amino acid asparagine (N) of the heavy chain variable region of the wild-type anti-CD3 antibody is mutated to glutamine (Q); taking CD3-HC-G102H as an example, it means that the 102nd amino acid glycine (G) of the heavy chain variable region of the wild-type anti-CD3 antibody is mutated to histidine (H). The CD3-HC mutants numbered 1 to 27 in the table are mutated using the amino acid sequence of the heavy chain variable region of the wild-type anti-CD3 antibody (SEQ ID NO: 1) as a template, and the amino acid sequence of the heavy chain constant region of the anti-CD3 antibody mutants is shown in SEQ ID NO: 3.
[0084] According to the test results in Table 1, it can be seen that compared with the wild-type anti-CD3 antibody, a total of 27 anti-CD3 antibody mutants with improved affinity for cell surface CD3 antigen were obtained, all of which were anti-CD3 antibody heavy chain mutants, and the mutation sites were located at positions 30, 102, 105, 106, 108, and 113, respectively.
[0085] Based on the screening of affinity determination results and the analysis of the amino acid properties of the mutation sites, at least one mutation site at position 30, position 102, position 105, position 106, position 108 and position 113 was selected to construct an anti-CD3 antibody mutant, which was further expressed and purified, and its physicochemical properties and affinity were analyzed.
[0086] Example 2: Construction and expression of anti-CD3 antibody mutants
[0087] 1. Construction of anti-CD3 antibody mutants
[0088] According to different candidate mutation sites (mutation sites at positions 102, 108 and 113) and their combinations, the full-length nucleotide sequences of 7 anti-CD3 antibody mutant IgGs were synthesized, i.e., the heavy chains of anti-CD3 antibody mutants 1 to 7. All sequences were entrusted to Nanjing GenScript Biotechnology Co., Ltd. for codon optimization (expression in mammalian cells) and then full gene synthesis. The target fragments were digested with XbaI and EcoRV and then connected to the pCDNA3.4 eukaryotic expression vector to obtain expression plasmids for expressing the full-length nucleotide sequences of each mutant IgG, and the correctness of the sequences was confirmed by sequencing.
[0089] The expression plasmid numbers of the wild-type anti-CD3 antibody and the mutant anti-CD3 antibody and the amino acid and nucleotide sequences of the proteins they express are as follows:
[0090] SEQ ID NO: 9: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 1 (223PR).
[0091] SEQ ID NO: 10: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 1 (223PL).
[0092] SEQ ID NO: 11: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 2 (224PR).
[0093] SEQ ID NO: 12: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 2 (224PL).
[0094] SEQ ID NO: 13: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 3 (225PR).
[0095] SEQ ID NO: 14: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 3 (225PL).
[0096] SEQ ID NO: 15: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 4 (226PR).
[0097] SEQ ID NO: 16: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 4 (226PL).
[0098] SEQ ID NO: 17: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 5 (227PR).
[0099] SEQ ID NO: 18: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 5 (227PL).
[0100] SEQ ID NO: 19: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 6 (228PR).
[0101] SEQ ID NO: 20: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 6 (228PL).
[0102] SEQ ID NO: 21: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody Mutant 7 (229PR).
[0103] SEQ ID NO: 22: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody Mutant 7 (229PL).
[0104] In addition, the mutation site at position 30, position 102, position 105, position 106, position 108, or position 113 of the wild-type heavy chain variable region of the anti-CD3 antibody in Example 1 was selected to obtain the heavy chains of the following anti-CD3 antibody mutants 8 to 18:
[0105] SEQ ID NO: 23: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody Mutant 8 (342 / CD3-HC-N030Q).
[0106] SEQ ID NO: 24: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody Mutant 8 (342 / CD3-HC-N030Q).
[0107] SEQ ID NO: 25: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 9 (342 / CD3-HC-G105A).
[0108] SEQ ID NO: 26: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 9 (342 / CD3-HC-G105A).
[0109] SEQ ID NO: 27: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 10 (342 / CD3-HC-G105H).
[0110] SEQ ID NO: 28: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 10 (342 / CD3-HC-G105H).
[0111] SEQ ID NO: 29: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 11 (342 / CD3-HC-G105N).
[0112] SEQ ID NO: 30: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 11 (342 / CD3-HC-G105N).
[0113] SEQ ID NO: 31: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 12 (342 / CD3-HC-G105P).
[0114] SEQ ID NO: 32: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 12 (342 / CD3-HC-G105P).
[0115] SEQ ID NO: 33: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 13 (342 / CD3-HC-G105Q).
[0116] SEQ ID NO: 34: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 13 (342 / CD3-HC-G105Q).
[0117] SEQ ID NO: 35: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 14 (342 / CD3-HC-N106D).
[0118] SEQ ID NO: 36: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 14 (342 / CD3-HC-N106D).
[0119] SEQ ID NO: 37: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 15 (342 / CD3-HC-Y108H).
[0120] SEQ ID NO: 38: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 15 (342 / CD3-HC-Y108H).
[0121] SEQ ID NO: 39: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 16 (342 / CD3-HC-Y108K).
[0122] SEQ ID NO: 40: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 16 (342 / CD3-HC-Y108K).
[0123] SEQ ID NO:41: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 17 (342 / CD3-HC-Y108R).
[0124] SEQ ID NO:42: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 17 (342 / CD3-HC-Y108R).
[0125] SEQ ID NO: 43: Amino acid sequence of the heavy chain variable region of anti-CD3 antibody mutant 18 (342 / CD3-HC-Y108S).
[0126] SEQ ID NO: 44: Nucleotide sequence of the heavy chain variable region of anti-CD3 antibody mutant 18 (342 / CD3-HC-Y108S).
[0127] In the present application, the antibody codes and corresponding mutation sites of the wild-type anti-CD3 antibody and the mutant anti-CD3 antibody are shown in Table 2 below.
[0128] Table 2. Antibody codes and corresponding mutation sites of wild-type anti-CD3 antibodies and anti-CD3 antibody mutants
[0129]
[0130]
[0131] 2. Expression of anti-CD3 antibody mutants
[0132] The wild-type anti-CD3 antibody and anti-CD3 antibody mutants shown in Table 2 were inoculated into SOB liquid culture medium containing ampicillin, respectively, and cultured overnight in a shaker at 37°C at 220 rpm. High-purity plasmids were extracted using an endotoxin-free extraction kit (purchased from Tiangen Biochemical Technology, catalog number DP117), and sequencing was performed to ensure the correctness of the plasmid sequence.
[0133] Cell transfection reagents were purchased from Thermo Fisher Scientific Inc., USA. Taking 25 mL of culture medium as an example, one day before transfection, ExpiCHO-S cells were cultured at 3×10 6 ~4×10 6 On the day of transfection, the cell density reached 7×10 6 ~10×10 6 cells / mL, and the cell viability should be >95%. Before transfection, dilute the cells to 6×10 6 The final density was 10 cells / mL and mixed gently.
[0134] Prepare transfection complex: first add 20 μg DNA to 1 mL Gibco TM OptiPRO TM Gently pipette and mix to make a DNA dilution solution; then add 80 μL ExpiFectamine TM CHO reagent was added to 920 μL Gibco TM OptiPRO TM In SFM, gently pipette to mix, and prepare the transfection reagent diluent; mix the two, gently pipette to mix, and let stand at room temperature for 5 minutes to form ExpiFectamine TM CHO reagent-DNA transfection complex. Add the transfection complex to ExpiCHO-S cells and shake thoroughly. Incubate the cells in a cell culture shaker (shaking speed 95 rpm) at 37°C, 90% humidity, and 8% CO2. 18 to 22 hours after transfection, add 150 μL ExpiFectamine TM CHO Enhancer and 6mL ExpiCHO TM Finally, the cells were placed in a shaker for further culture, and the supernatant was collected 7 to 10 days after transfection.
[0135] 3. Purification and stability determination of anti-CD3 antibody mutants
[0136] Protein purification: IgG was separated and purified using Protein A agarose purification resin (BBI Life Sciences, Catalog No. C600953). The expression supernatant was collected and purified 7 to 10 days after cell transfection. First, the cells were removed by centrifugation at 200 to 300 × g for 3 minutes, then impurities were removed by centrifugation at 3000 to 4000 × g for 30 minutes, and then filtered at 0.22 μm. The protein purification process was carried out in a low-temperature chromatography cabinet (purchased from Boyikang Company). Before protein loading, its salt ion concentration was adjusted to 20 mM. At the same time, 10 column volumes of deionized water and 10 column volumes of Binding Buffer (BBI Life Sciences, Catalog No. C600482) were used to balance the Protein A column. After the protein was loaded, it was eluted with 10 column volumes of Binding Buffer, and then with Elution Buffer (BBI Life Sciences, Catalog No. C600481). 3 mL of eluate was collected in each tube, and a total of 10 to 12 tubes were collected. Neutralization Buffer (BBI Life Sciences, Catalog No. B548142) was used in advance to adjust the pH value of the protein eluate to about 7. After the elution was completed, 10 column volumes of Binding Buffer and deionized water were used to rinse the equilibrium purification column, and finally sealed with 20% ethanol at 4°C.
[0137] Stability determination: The collected protein was placed in an ultrafiltration tube, centrifuged at 3000-4000 rpm at 4°C for concentration, and the protein buffer was replaced with PBS buffer (pH 7.4). The concentrated protein was filtered through a 0.22 μm filter membrane and stored at 4°C. The concentration of the target protein was determined using NanoDrop (purchased from Thermo Fisher Scientific, USA). The purity and molecular weight of the target protein were analyzed by SDS-PAGE and SEC-HPLC.
[0138] Thermal stability test of antibodies: In this application, the melting temperature (Tm) is used to characterize the thermal stability of antibodies. The higher the Tm value, the stronger the thermal stability of the antibody. In order to detect the thermal stability of the protein, the purified protein was stained with SYPRO TM The Orange Protein Gel Stain Kit (purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd.) was used to detect its Tm value. The staining solution was added to the 10 μM protein sample to prepare a 25 μL reaction system, centrifuged to mix evenly, and kept away from light as much as possible. The test was performed in a qPCR instrument (purchased from Hongshi Technology), and the temperature change was set to 0.01 °C / s, and the temperature change range was 25 °C to 95 °C.
[0139] Figure 1 This is a non-reducing SDS-PAGE electrophoresis diagram of the anti-CD3 antibody mutants 1 to 7 provided in the examples of the present application; Figure 1As shown, the protein purity of anti-CD3 antibody mutants 1 to 7 was comparable, all above 80%.
[0140] Figure 2 The reduced SDS-PAGE electrophoresis diagram of the anti-CD3 antibody mutants 1 to 7 provided in the examples of this application; Figure 2 As shown, under reducing conditions, the heavy chain and light chain bands of the anti-CD3 antibody mutants were located at approximately 55 kDa and 25 kDa, respectively.
[0141] Figure 3 This is the SEC-HPLC chromatogram of the wild-type anti-CD3 antibody provided in the examples of the present application, Figure 4a This is the SEC-HPLC chromatogram of the anti-CD3 antibody mutants 1 to 9 provided in the examples of the present application, Figure 4b The SEC-HPLC chromatograms of the anti-CD3 antibody mutants 10 to 18 provided in the examples of the present application are as follows: Figure 3 to Figure 4b As shown in the data in Table 3, although anti-CD3 antibody mutants 1 to 10 have a small area of aggregate peaks, they did not reach the set minimum product peak conditions, and they were better than the anti-CD3 antibody wild type in inhibiting the generation of aggregates; although anti-CD3 antibody mutants 12 to 16 have a small area of aggregate peaks, they did not reach the set minimum product peak conditions, and they were better than the anti-CD3 antibody wild type in inhibiting the generation of aggregates; although anti-CD3 antibody mutants 11, 17, and 18 have aggregates, their percentages are not higher than 7%, and they are still better than the anti-CD3 antibody wild type in inhibiting the generation of aggregates. Further, the purified yield, percentage of aggregates, and stability test results of the anti-CD3 antibody wild type and anti-CD3 antibody mutants are shown in Table 3.
[0142] Table 3. Purification and stability test results of anti-CD3 antibody wild type and anti-CD3 antibody mutants
[0143]
[0144]
[0145] The protein yields of the proteins obtained by transient expression after purification on a protein A column are shown in Table 3. Specifically, under the same expression and purification conditions, except for anti-CD3 antibody mutant 5 (No. 342 / 227) and mutant 10 (No. 342 / CD3-HC-G105H), the yields of the remaining 16 mutants were higher than that of the anti-CD3 antibody wild type (No. 341 / 342). The Tm values of the 18 anti-CD3 antibody mutants were comparable to those of the anti-CD3 antibody wild type, among which the Tm values of anti-CD3 antibody mutant 2 (No. 342 / 224) and mutant 18 (No. 342 / CD3-HC-Y108S) were higher than those of the anti-CD3 antibody wild type, indicating that they had higher thermal stability.
[0146] Combining the antibody production and stability data of the anti-CD3 antibody wild type and the anti-CD3 antibody mutant in the table, it can be seen that the sequence mutation modification described in the present invention can significantly increase the production of anti-CD3 antibodies, reduce the generation of aggregates, and improve its thermal stability to a certain extent, thereby obtaining a more stable antibody protein.
[0147] Fourth. Determination of binding activity of anti-CD3 antibody mutants at the cellular level
[0148] In the present application, flow cytometry fluorescence sorting technology (FACS) is used to determine the binding activity of anti-CD3 antibody mutants, and the specific steps include:
[0149] Jurkat cell line, a human lymphocytic leukemia cell line that highly expresses natural CD3, was cultured in RPMI-1640 medium (purchased from Thermo Fisher Scientific, USA) containing 10% FBS (purchased from Thermo Fisher Scientific, USA) and double antibody (purchased from Shanghai Biotime Biotechnology Co., Ltd.), and passaged every 2 to 3 days.
[0150] Jurkat cells in the logarithmic growth phase were taken, and after cell counting, the cell pellet was washed with 1×PBS buffer and centrifuged at 250×g for 5 minutes. The cells were resuspended in 1×PBS buffer and inoculated into 96-well V-bottom culture plates (purchased from NEST Company), with 50 μL of cell suspension per well and a cell density of 5×10 5Cells / well. Add 50 μL of the test antibody diluted in series to each well, so that the final protein concentration is 500nM, 100nM, 20nM, 4nM, 0.8nM, 0.16nM, 0.032nM, 0.0064nM, 0.00128nM, 0.000256nM, 0.0000512nM and 0.00001024nM, respectively. The cell wells without antibody were used as negative controls and incubated at 4°C for 1 hour. Wash the cells twice with PBS, centrifuge at 250×g for 5 minutes each time. Add 100 μL of the secondary antibody Goat anti-Human IgG Fc Secondary Antibody PE (purchased from Thermo Fisher Scientific, Cat. No. 12-4998-82) diluted 1:200 in PBS and incubate at 4°C for 30 minutes. The cells were washed twice with PBS, centrifuged at 250 × g for 5 min each time, resuspended in 120 μL PBS, and the mean fluorescence intensity values were read using a CytoFLEX flow cytometer (purchased from Beckman Coulter). Graphpad Prism was used for result analysis and data processing.
[0151] The target binding activity curves of the wild-type anti-CD3 antibody and anti-CD3 antibody mutants 1 to 7 at different concentrations on the Jurkat cell line are shown in Figure 2. Figure 5 The EC50 concentrations calculated from the binding activity curves are shown in Table 4.
[0152] Table 4. EC50 concentrations of wild-type anti-CD3 antibody and anti-CD3 antibody mutants 1 to 7 binding to the target at the cellular level
[0153]
[0154] It can be seen from the data in Table 4 that the CD3 binding EC50 concentrations of the 7 anti-CD3 antibody mutants are significantly lower than those of the anti-CD3 antibody wild type, and it can be seen that the binding activity of the 7 anti-CD3 antibody mutants to the CD3 antigen at the cellular level is significantly improved. It can be seen that after the sequence mutation modification described in the present invention, the anti-CD3 antibody mutants only need a lower dose (about 1 / 2 to 1 / 4 of the dose of the anti-CD3 antibody wild type) to achieve CD3 affinity equivalent to that of the anti-CD3 antibody wild type.
[0155] According to the screening of affinity determination results and the analysis of the amino acid properties of mutation sites, this application has selected 7 anti-CD3 antibody mutants (anti-CD3 antibody mutants 1 to 7), which can significantly improve the ability of anti-CD3 antibodies to bind to cell surface CD3 antigens, and at the same time, increase the yield of anti-CD3 antibodies, greatly reduce the generation of aggregates, and improve its thermal stability to a certain extent, and obtain more stable antibody proteins. Compared with the prior art, it has clear beneficial effects.
[0156] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. An anti-CD3 antibody mutant, It is characterized in that The anti-CD3 antibody mutant comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is obtained by mutating at least one amino acid in the amino acid sequence of the heavy chain variable region of the wild-type anti-CD3 antibody shown in SEQ ID NO: 1; The mutation sites of the amino acid sequence shown in SEQ ID NO: 1 include at least one mutation site among positions 30, 102, 105, 106, 108 and 113.
2. The anti-CD3 antibody mutant according to claim 1, It is characterized in that It meets at least one of the following characteristics: (1) N at position 30 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with Q; (2) G at position 102 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of H, Q, and S; (3) G at position 105 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, H, M, N, P, and Q; (4) N at position 106 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, D, K, Q, and Y; (5) Y at position 108 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, D, F, G, H, I, K, L, R, S, or W; (6) The A at position 113 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with E.
3. The anti-CD3 antibody mutant according to claim 1, It is characterized in that It meets at least one of the following characteristics: (1) N at position 30 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with Q; (2) G at position 102 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with S; (3) G at position 105 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of A, H, N, P, and Q; (4) N at position 106 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with D; (5) Y at position 108 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with any one of G, H, K, R, and S; (6) The A at position 113 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with E.
4. The anti-CD3 antibody mutant according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is selected from any one of the amino acid sequence shown in SEQ ID NO:9, the amino acid sequence shown in SEQ ID NO:11, the amino acid sequence shown in SEQ ID NO:13, the amino acid sequence shown in SEQ ID NO:15, the amino acid sequence shown in SEQ ID NO:17, the amino acid sequence shown in SEQ ID NO:19, the amino acid sequence shown in SEQ ID NO:21, the amino acid sequence shown in SEQ ID NO:23, the amino acid sequence shown in SEQ ID NO:25, the amino acid sequence shown in SEQ ID NO:27, the amino acid sequence shown in SEQ ID NO:29, the amino acid sequence shown in SEQ ID NO:31, the amino acid sequence shown in SEQ ID NO:33, the amino acid sequence shown in SEQ ID NO:35, the amino acid sequence shown in SEQ ID NO:37, the amino acid sequence shown in SEQ ID NO:39, the amino acid sequence shown in SEQ ID NO:41 and the amino acid sequence shown in SEQ ID NO:
43.
5. The anti-CD3 antibody mutant according to claim 4, It is characterized in that The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:9, which is encoded by the nucleotide sequence shown in SEQ ID NO:10; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 11, which is encoded by the nucleotide sequence shown in SEQ ID NO: 12; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 13, which is encoded by the nucleotide sequence shown in SEQ ID NO: 14; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 15, which is encoded by the nucleotide sequence shown in SEQ ID NO: 16; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 17, which is encoded by the nucleotide sequence shown in SEQ ID NO: 18; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 19, which is encoded by the nucleotide sequence shown in SEQ ID NO: 20; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 21, which is encoded by the nucleotide sequence shown in SEQ ID NO: 22; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 23, which is encoded by the nucleotide sequence shown in SEQ ID NO: 24; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 25, which is encoded by the nucleotide sequence shown in SEQ ID NO: 26; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 27, which is encoded by the nucleotide sequence shown in SEQ ID NO: 28; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 29, which is encoded by the nucleotide sequence shown in SEQ ID NO: 30; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:31, which is encoded by the nucleotide sequence shown in SEQ ID NO:32; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 33, which is encoded by the nucleotide sequence shown in SEQ ID NO: 34; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:35, which is encoded by the nucleotide sequence shown in SEQ ID NO:36; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO: 37, which is encoded by the nucleotide sequence shown in SEQ ID NO: 38; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:39, which is encoded by the nucleotide sequence shown in SEQ ID NO:40; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:41, which is encoded by the nucleotide sequence shown in SEQ ID NO:42; The amino acid sequence of the heavy chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:43, which is encoded by the nucleotide sequence shown in SEQ ID NO:
44.
6. The anti-CD3 antibody mutant according to claim 1, It is characterized in that The amino acid sequence of the light chain variable region of the anti-CD3 antibody mutant is shown in SEQ ID NO:5, and the nucleotide sequence of the light chain variable region is shown in SEQ ID NO:
6.
7. A nucleotide sequence of a heavy chain variable region of an anti-CD3 antibody mutant, It is characterized in that It encodes the anti-CD3 antibody mutant according to any one of claims 1 to 6.
8. The nucleotide sequence of the heavy chain variable region of the anti-CD3 antibody mutant according to claim 7, It is characterized in that The nucleotide sequence of the heavy chain variable region of the anti-CD3 antibody mutant is selected from any one of the nucleotide sequence shown in SEQ ID NO: 10, the nucleotide sequence shown in SEQ ID NO: 12, the nucleotide sequence shown in SEQ ID NO: 14, the nucleotide sequence shown in SEQ ID NO: 16, the nucleotide sequence shown in SEQ ID NO: 18, the nucleotide sequence shown in SEQ ID NO: 20, the nucleotide sequence shown in SEQ ID NO: 22, the nucleotide sequence shown in SEQ ID NO: 24, the nucleotide sequence shown in SEQ ID NO: 26, the nucleotide sequence shown in SEQ ID NO: 28, the nucleotide sequence shown in SEQ ID NO: 30, the nucleotide sequence shown in SEQ ID NO: 32, the nucleotide sequence shown in SEQ ID NO: 34, the nucleotide sequence shown in SEQ ID NO: 36, the nucleotide sequence shown in SEQ ID NO: 38, the nucleotide sequence shown in SEQ ID NO: 40, the nucleotide sequence shown in SEQ ID NO: 42 and the nucleotide sequence shown in SEQ ID NO:
44.
9. A recombinant expression vector, It is characterized in that The recombinant expression vector comprises the nucleotide sequence of claim 7 or 8.
10. The recombinant expression vector according to claim 9, It is characterized in that The recombinant expression vector is a eukaryotic expression vector, and the eukaryotic expression vector comprises the nucleotide sequence according to claim 7 or 8.
11. Use of the anti-CD3 antibody mutant according to any one of claims 1 to 6 in a drug for inhibiting or treating cancer.
12. The use according to claim 11, It is characterized in that The cancer is selected from the following cancers or occurs in the following sites: colon cancer, breast cancer, ovarian cancer, pancreatic cancer, stomach cancer, prostate cancer, kidney cancer, cervical cancer, bone marrow cancer, lymphoma cancer, leukemia cancer, thyroid cancer, endometrial cancer, uterine cancer, bladder cancer, neuroendocrine cancer, head and neck cancer, liver cancer, nasopharyngeal cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, melanoma, basal cell skin cancer, squamous cell skin cancer, dermatofibrosarcoma protuberans, Merkel cell carcinoma, glioblastoma, glioma, sarcoma, mesothelioma, and myelodysplastic syndrome.
